| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.panchsheel.com | |
| Market Cap | 232.66 Cr. | |
| Enterprise Value(EV) | 226.53 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 6.24 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | 37.19 | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 28.96 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | 49.95 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | 4.64 | Calculated using Price: 231.95 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.00 Cr. | 10,030,800 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Panchsheel Organics, incorporated in the year 1989, is a part of the Pharmaceutical Division of the Turakhia Brothers Group. Turakhia Brothers was founded in 1975 in the Mumbai, India. The Turakhia Group, promoters of the company, are engaged in the import-export trade of pharmaceutical raw materials since the past 25 years. Panchsheel exports bulk actives to over 60 countries mainly in Europe, South East Asia, Japan and Latin America. The company's inherent strength lies in identifying relevant bulk drugs and selling them at affordable prices across the world. Skilled people, modern equipment and broad experience contribute to the strength of Panchsheel Organics. Skilled production teams assure flexibility, efficiency and consistent standard in drugs manufacturing. The R & D division of Panchsheel backed with experienced, highly qualified teams provide sophisticated innovative solutions. Skilled production teams assure flexibility, efficiency and consistent standard in chemical manufacturing. The current practices at Panchsheel are adherence to high quality and safety standards as well as full compliance with GMP procedures. The gaseous emissions are properly controlled and waste water is treated properly so as to ensure compliance with local and international risk, minimizing damage to persons and environment. Panchsheel has free capacity in its five production sites in all over India. This capacity is would be used by interested companies for development and custom synthesis on strictly confidential terms. Some of the basic operations carried out by Panchsheel are:
Product range of the company includes: |
||
Company Profile
Panchsheel Organics, incorporated in the year 1989, is a part of the Pharmaceutical Division of the Turakhia Brothers Group. Turakhia Brothers was founded in 1975 in the Mumbai, India. The Turakhia Group, promoters of the company, are engaged in the import-export trade of pharmaceutical raw materials since the past 25 years.
Panchsheel exports bulk actives to over 60 countries mainly in Europe, South East Asia, Japan and Latin America. The company's inherent strength lies in identifying relevant bulk drugs and selling them at affordable prices across the world.
Skilled people, modern equipment and broad experience contribute to the strength of Panchsheel Organics. Skilled production teams assure flexibility, efficiency and consistent standard in drugs manufacturing.
The R & D division of Panchsheel backed with experienced, highly qualified teams provide sophisticated innovative solutions. Skilled production teams assure flexibility, efficiency and consistent standard in chemical manufacturing.
The current practices at Panchsheel are adherence to high quality and safety standards as well as full compliance with GMP procedures. The gaseous emissions are properly controlled and waste water is treated properly so as to ensure compliance with local and international risk, minimizing damage to persons and environment.
Panchsheel has free capacity in its five production sites in all over India. This capacity is would be used by interested companies for development and custom synthesis on strictly confidential terms.
Some of the basic operations carried out by Panchsheel are:
Product range of the company includes: Bulk Drugs - Alendronate Sodium Trihydrate, Isoxsuprine HCL, Alprazolam, Itraconazole Pellets 22%, Amitriptyline HCL BP/USP, Ketoconazole BP/USP, Amlodipine Besylate etc.
| 1 Day |
|
+2.02% |
| 1 Week |
|
+17.83% |
| 1 Month |
|
+36.80% |
| 3 Month |
|
+52.75% |
| 6 Month |
|
+137.78% |
| 1 Year |
|
+372.60% |
| 2 Year |
|
+935.49% |
| 5 Year |
|
+332.34% |
| 10 Year |
|
+2628.82% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 8.01 | 10.49 | 10.55 | 15.43 | 14.48 | 14.57 | 14.05 | 16.08 | 13.35 | |
| Return on Capital Employed (%) | 11.05 | 15.09 | 14.28 | 18.51 | 19.66 | 18.21 | 17.77 | 20.31 | 18.60 | |
| Return on Assets (%) | 4.11 | 5.22 | 5.55 | 8.66 | 8.43 | 8.55 | 8.76 | 10.79 | 8.94 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 16 | 18 | 19 | 21 | 23 | 27 | 30 | 35 | 40 | 43 | |
| Non Curr. Liab. | 2 | 3 | 4 | 4 | 2 | 1 | 0 | 1 | 2 | 2 | |
| Curr. Liab. | 14 | 15 | 11 | 12 | 14 | 19 | 15 | 17 | 18 | 16 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 32 | 35 | 33 | 37 | 39 | 47 | 45 | 53 | 59 | 61 | |
| Non Curr. Assets | 8 | 8 | 7 | 9 | 10 | 10 | 9 | 11 | 15 | 9 | |
| Curr. Assets | 24 | 27 | 26 | 28 | 29 | 37 | 36 | 42 | 45 | 52 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 32 | 35 | 33 | 37 | 39 | 47 | 45 | 53 | 59 | 61 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 33 | 39 | 36 | 40 | 40 | 42 | 48 | 51 | 49 | 58 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 33 | 39 | 36 | 41 | 40 | 42 | 49 | 51 | 50 | 58 | |
| Total Expenditure | -30 | -35 | -31 | -35 | -33 | -36 | -41 | -42 | -41 | -48 | |
| PBIDT | 3 | 5 | 5 | 6 | 7 | 7 | 7 | 9 | 9 | 11 | |
| Interest | -1 | -1 | -1 | -1 | 0 | -1 | 0 | 0 | 0 | 0 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -2 | -2 | -3 | |
| Exceptional Items | |||||||||||
| PAT | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 6 | |
| Adjusted EPS | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 6 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 1 | 1 | 3 | 1 | 3 | 5 | 3 | 2 | 5 | 5 | |
| Cash Fr. Inv. | 0 | -1 | -1 | -1 | -2 | -3 | -1 | -1 | -3 | -1 | |
| Cash Fr. Finan. | -2 | 0 | -2 | 0 | -1 | -1 | -2 | -2 | -1 | -2 | |
| Net Change | -1 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 1 | 3 | |
| Cash & Cash Eqvt | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 4 |
|
Sat, 14 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.
Date: 14/05/2022 |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sat, 07 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the copies of the newspaper advertisement of the Notice of the 1st Extra-ordinary General Meeting of the Company for the financial year 2022-23 to be held on Friday May 27 2022 published on May 6 2022 in Business Standard newspaper in Hindi and English language.The aforesaid newspaper clippings are also available on website of the Company www.panchsheelorgancis.com.Kindly take the same on record. |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Thu, 05 May 2022
Notice Of Extra-Ordinary General Meeting To Be Held On May 27 2022 Notice convening the Extra-ordinary General Meeting of the members of the Company for the financial year 2022-23 scheduled to be held on Friday May 27 2022 |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Wed, 18 May 2022 |
Close Crossing 52 Week High
|
Opening at High
|
Closing Above Previous High
|
Closing Above Previous High For 3 Days
|
Making Higher Highs for 3 days
|
Equities
M.F.
Sectors